These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18926575)

  • 21. Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis.
    Cosentino M; Zaffaroni M; Ferrari M; Marino F; Bombelli R; Rasini E; Frigo G; Ghezzi A; Comi G; Lecchini S
    J Neuroimmunol; 2005 May; 162(1-2):112-21. PubMed ID: 15833366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients.
    Alidoost F; Gharagozloo M; Bagherpour B; Jafarian A; Sajjadi SE; Hourfar H; Moayedi B
    Int Immunopharmacol; 2006 Aug; 6(8):1305-10. PubMed ID: 16782543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolation and immunomodulatory effect of flavonoids from Syzygium samarangense.
    Kuo YC; Yang LM; Lin LC
    Planta Med; 2004 Dec; 70(12):1237-9. PubMed ID: 15643565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atopic dermatitis in adults: evaluation of peripheral blood mononuclear cells proliferation response to Staphylococcus aureus enterotoxins A and B and analysis of interleukin-18 secretion.
    Orfali RL; Sato MN; Takaoka R; Azor MH; Rivitti EA; Hanifin JM; Aoki V
    Exp Dermatol; 2009 Jul; 18(7):628-33. PubMed ID: 19469892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
    Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
    Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
    Comabella M; Río J; Espejo C; Ruiz de Villa M; Al-Zayat H; Nos C; Deisenhammer F; Baranzini SE; Nonell L; López C; Julià E; Oksenberg JR; Montalban X
    Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential immunomodulatory effects of plant lectins in Schistosoma mansoni infection.
    Reis EA; Athanazio DA; Cavada BS; Teixeira EH; de Paulo Teixeira Pinto V; Carmo TM; Reis A; Trocolli G; Croda J; Harn D; Barral-Netto M; Reis MG
    Acta Trop; 2008; 108(2-3):160-5. PubMed ID: 18579103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls.
    Vanderlocht J; Hendriks JJ; Venken K; Stinissen P; Hellings N
    J Neuroimmunol; 2006 Aug; 177(1-2):189-200. PubMed ID: 16797728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased interferon-α production in response to CpG DNA dysregulates cytokine responses in patients with multiple sclerosis.
    Hirotani M; Niino M; Fukazawa T; Yaguchi H; Nakamura M; Kikuchi S; Sasaki H
    Clin Immunol; 2012 May; 143(2):145-51. PubMed ID: 22386492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-17 in transverse myelitis and multiple sclerosis.
    Graber JJ; Allie SR; Mullen KM; Jones MV; Wang T; Krishnan C; Kaplin AI; Nath A; Kerr DA; Calabresi PA
    J Neuroimmunol; 2008 May; 196(1-2):124-32. PubMed ID: 18417225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ozone on isolated peripheral blood mononuclear cells.
    Larini A; Bocci V
    Toxicol In Vitro; 2005 Feb; 19(1):55-61. PubMed ID: 15582356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.
    Ysrraelit MC; Gaitán MI; Lopez AS; Correale J
    Neurology; 2008 Dec; 71(24):1948-54. PubMed ID: 19064876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of nano-silver on the proliferation and cytokine expression by peripheral blood mononuclear cells.
    Shin SH; Ye MK; Kim HS; Kang HS
    Int Immunopharmacol; 2007 Dec; 7(13):1813-8. PubMed ID: 17996693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.
    Chen M; Chen G; Nie H; Zhang X; Niu X; Zang YC; Skinner SM; Zhang JZ; Killian JM; Hong J
    Eur J Immunol; 2009 Sep; 39(9):2525-36. PubMed ID: 19670379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis.
    Petersen T; Møller-Larsen A; Thiel S; Brudek T; Hansen TK; Christensen T
    J Neuroimmunol; 2009 Oct; 215(1-2):108-16. PubMed ID: 19766328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection.
    Nakatsuji Y; Nakano M; Moriya M; Kishigami H; Tatsumi C; Tada S; Sadahiro S; Naka T; Mitani K; Funauchi M; Azuma T; Watanabe S; Kinoshita M; Kajiyama K; Yuasa Y; Kaido M; Takahashi MP; Naba I; Hazama T; Sakoda S;
    Cytokine; 2006 Oct; 36(1-2):69-74. PubMed ID: 17161613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An experimental model for the determination of immunomodulating effects by volatile compounds.
    Wichmann G; Mühlenberg J; Fischäder G; Kulla C; Rehwagen M; Herbarth O; Lehmann I
    Toxicol In Vitro; 2005 Aug; 19(5):685-93. PubMed ID: 15885978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral and immunoregulatory effect of a novel exopolysaccharide from a marine thermotolerant Bacillus licheniformis.
    Arena A; Maugeri TL; Pavone B; Iannello D; Gugliandolo C; Bisignano G
    Int Immunopharmacol; 2006 Jan; 6(1):8-13. PubMed ID: 16332508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
    Drulovic J; Savic E; Pekmezovic T; Mesaros S; Stojsavljevic N; Dujmovic-Basuroski I; Kostic J; Vasic V; Mostarica Stojkovic M; Popadic D
    J Neuroimmunol; 2009 Oct; 215(1-2):90-5. PubMed ID: 19695714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.